No Data
Arbutus Biopharma Shares Are Trading Higher After the Company Presented Clinical Trial Data From Its Two HBV Assets.
Express News | Arbutus's Imdusiran Plus VTP-300 And Low-Dose Nivolumab Achieve HBsAg Loss And Seroconversion In CHBV Patients, New Phase 2a Data Reveal At EASL 2025
Arbutus Biopharma Showcases Promising Hepatitis B Treatments at EASL Congress 2025
Express News | Arbutus Biopharma To Present Key Hepatitis B Data, Including Late-Breaker, At EASL Congress 2025
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk